Researchers from Würzburg and Stony Brook have found a new weak spot in the bacterium that causes tuberculosis: Blocking a specific enzyme involved in the cholesterol catabolism could disable the bacteria.
In 2012, there were around 8.6 million cases of tuberculosis worldwide resulting in 1.3 million associated deaths according to the World Health Organisation WHO. About five percent of infections were caused by multidrug-resistant pathogens, a trend that is on the rise.
Scientists are therefore seeking new effective ways to tackle the tuberculosis bacteria in the future. Professor Caroline Kisker and her team have devoted their research to this topic: At the University of Würzburg’s Rudolf-Virchow-Center for Experimental Biomedicine, they are studying the bacterial enzymes to pinpoint new vulnerable points.
Enzyme-steroid interaction opens up new prospects
The Würzburg researchers are looking into the pathogens' cholesterol metabolism among others. The enzyme FadA5 is of major interest in this context as it is needed by the bacillus to keep up chronic infection. Teaming up with researchers of Stony Brook University (US), Kisker and her team have now analysed the exact structure of the enzyme – and identified a potential new target for drugs.
"We inserted a steroid molecule into the enzyme's active centre and analysed the resulting structure," the Würzburg professor explains. This finding helps to design molecules that fit exactly into the active centre and block it with the aim to completely disable the enzyme FadA5, as the research group reports in the January issue of "Structure" journal.
Drug specifically targets the bacterium
A potential problem, however, is that the human organism uses enzymes which are similar to the FadA5 from the tuberculosis bacilli. Hence, it is conceivable that a new drug not only affects the bacteria, but harms the human body as well.
Therefore, Kisker's team analysed the human enzymes, too. The result was promising: "Comparing the structures showed that it should be possible to block the bacterial enzyme specifically," the professor further. Thus, an inhibiting drug should only harm the bacteria but not the human enzymes.
"The steroid is a solid basis for us to develop new inhibiting drugs," Kisker says. To pursue this goal, she has teamed up with other work groups, including that of Professor Christoph Sotriffer of the Würzburg Pharmaceutical Chemistry Department. Their aim is to find a drug that specifically inhibits the FadA5 enzyme of the tuberculosis pathogens.
Schaefer et al.: "FadA5 a thiolase from Mycobacterium tuberculosis – a unique steroid-binding pocket reveals the potential for drug development against tuberculosis", Structure, published online, 2014, December 4, DOI: http://dx.doi.org/10.1016/j.str.2014.10.010
Prof. Dr. Caroline Kisker, Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Phone +49 931 31-80381, firstname.lastname@example.org
Robert Emmerich | Julius-Maximilians-Universität Würzburg
Cancer diagnosis: no more needles?
25.05.2018 | Christian-Albrechts-Universität zu Kiel
Less is more? Gene switch for healthy aging found
25.05.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences